Imbruvica is a small molecule anti-cancer drug that targets B-cell malignancies. In November 2013 imbruvica was approved by the FDA for the treatment of mantle cell lymphoma, and later in February 2014 for the treatment of chronic lymphocytic leukemia. Imbruvica is also indicated for the treatment of patients with Waldenström’s Macroglobulinemia (WM). Imbruvica is marketed under the brand Imbruvica® by Janssen Biotech, Inc., but was first designed and synthesized at Celera Genomics in 2007.
In patients with recurrent B-cell lymphoma > 90% occupancy of the BTK active site in peripheral blood mononuclear cells was observed up to 24 hours after imbruvica doses of ≥ 2.5 mg/kg/day (≥ 175 mg/day for average weight of 70 kg).
Strength: 140 Mg
Pill Imprint: Ibr 140 Mg
View Images & Details